The global human cytomegalovirus 65 kDa phosphoprotein market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Human cytomegalovirus (HCMV) causes lifelong infection in humans and is generally asymptomatic in healthy hosts. However, it can cause severe and sometimes fatal diseases in immunocompromised individuals. The major factor accelerating the growth of the market is the increasing prevalence of HCMV disease across the globe.
According to the British Society for Immunology, HCMV has a prevalence of 55-100% within the human population and is the leading infectious cause of congenital abnormalities in the western globe while affecting 1-2.5% of all live births. Additionally, it can cause significant morbidity that includes low birth weight, hearing loss, visual impairment, microcephaly, hepatosplenomegaly, and varying degrees of mental retardation as well as a serious disease in organ transplant recipients and AIDS patients. Hence, the increasing prevalence of this disease is driving the growth of the global human cytomegalovirus 65 kDa phosphoprotein market.
To Request a Sample of our Report on Human Cytomegalovirus 65 kDa Phosphoprotein Market: https://www.omrglobal.com/request-sample/human-cytomegalovirus-65-kda-phosphoprotein-market
Some major players operating in the market include Astellas Pharma Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2021, Takeda Pharmaceuticals Co. Ltd. announced the approval of Livtencity (maribavir) from the US FDA. It is used for the treatment of adults and pediatric patients with post-transplant cytomegalovirus (CMV) disease that does not respond to the available antiviral treatment for CMV.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Astellas Pharma Inc., among others.
(Get 15% Discount on Buying this Report)
A full Report of Human Cytomegalovirus 65 kDa Phosphoprotein Market is Available @ https://www.omrglobal.com/industry-reports/human-cytomegalovirus-65-kda-phosphoprotein-market
Global Human Cytomegalovirus 65 kDa Phosphoprotein Market Report by Segment
By Type
- HB-101
- CyMVectin
- ASP-0113
- PepVax
- Others
By Application
- Brain Tumor
- Hematological Tumor
- Kidney Transplant Rejection
- Liver Transplant Rejection
- Others
Global Human Cytomegalovirus 65 kDa Phosphoprotein Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
